Profile and Management Outcomes of Neurotrophic Keratitis at A Tertiary Eye Hospital in Saudi Arabia: A Cohort Study

沙特阿拉伯一家三级眼科医院神经营养性角膜炎患者的特征和治疗结果:一项队列研究

阅读:1

Abstract

PURPOSE: To evaluate the neurotrophic keratitis (NK) profile, management outcomes, and determinants at a tertiary eye hospital in Saudi Arabia. METHODS: This historical cohort comprised patients with the ICD-10 code of H16.239 who presented and were treated from 2014 to 2024. The classification of NK based on Mackie's criteria; NK was classified into stages 1-3. Demographic data, NK etiology, and both medical and surgical therapeutic interventions were analyzed. We correlated these outcomes with the etiology, stages, and treatment modalities. RESULTS: The cohort had 94 eyes of 80 NK patients in stage 1 (6, 6%), stage 2 (69, 74%), and stage 3 (19, 20%). Seventy-Three (77.7%) eyes showed reduced corneal sensation, 14 (15%) eyes showed intact corneal sensation, and 7 (7.4%) eyes showed no discernible corneal sensation. Herpes zoster (22.5%) was the most common infectious etiology followed by herpes simplex (2.5%). Trigeminal palsy was observed in 24 (30%) eyes. Iatrogenic NK was present in 12 (15%) eyes. Decreased vision (88.1%), redness of the eyes (47.6%), and swollen lids (34.5%) were the main symptoms. The most frequently performed procedures included amniotic membrane transplantation (AMT) (45.7%), tarsorrhaphy (36.2%), and corneal gluing (17%). At the last follow-up after management, the Best Corrected Visual Acuity (BCVA) was 1.5 logMAR in eyes affected by NK. At presentation (78.2%) and after treatment (38.2%), eyes with NK had severe visual impairment (SVI). CONCLUSION: The management of NK presents significant challenges but offers potential rewards, as it facilitates ocular preservation and may enable visual restoration following initial therapeutic intervention.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。